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INTRODUCTION
Celiac disease represents an autoimmune dis-
ease induced by gliadin and related prolamins 
present in gluten of wheat, barley and rye 
grains [1-4]. It is primarily found in Caucasians 
(1:100), while being considerably or exception-
ally rarer in the population of other races [3-
8]. Similarly to other autoimmune diseases it is 
more frequent in females [4]. The basis of the 
disease and the key finding in its diagnostics 
is gluten-sensitive enteropathy, i.e. a nonspe-
cific inflammation of the small intestinal mu-
cosa that resolves by gluten-free diet [1, 2, 3, 
9, 10]. Beside enteropathy, either symptomatic 
or asymptomatic, the disease is also character-
ized by different extraintestinal manifestations, 
as well as potentially severe complications [11, 
12]. As it is disclosed in only 1:5-13 cases, to-
day celiac disease is ranked as the most fre-
quent chronic disease of the modern man [4, 
9, 10, 13]. Owing to the up-to-date knowledge 
and diagnostic possibilities, over the last years 
the rate of verified disease, particularly atypical 
and subclinical form, is continually increasing 
both in the developed and developing coun-
tries [13-17].
PATHOGENESIS
Celiac disease belongs to the group of chronic 
inflammatory diseases of multifactorial nature 
[1-4]. Beside polygenic predisposition and ex-
posure to gluten as the trigger of autoimmune 
process, some other factors also have essential 
participation in the expression of the disease, 
such as too early (<17 weeks) or too late (≥26 
weeks), introduction of gluten into the child’s 
diet, absent breastfeeding at that time, rota-
virus gastroenteritis and other [6, 18-28]. In 
contribution to the prevailing role of polygenic 
heredity in the disease occurrence speaks its 
highly variable frequency in different popula-
tions, as well as a high rate of its presence in 
one-egg twins (~100%) and first-line relatives 
(10-20%) [2-4, 10]. HLA class II genes play a 
central role in the hereditary predisposition 
to the disease, but also with the unavoidable 
participation of other genetic loci [1-4, 10, 
29]. This is proved by the fact that 85-95% of 
examinees with celiac disease carry the HLA 
DQ2 haplotype, while in 5-15% the HLA DQ8 
is registered [1-4, 30, 31, 32]. In addition, a 
correlation between these two haplotypes and 
celiac disease prevalence worldwide has been 
confirmed [4]. However, the disease expres-
sion, beside HLA DQ2 and/or DQ8 gene and 
exposure to gluten, also requires non-HLA 
genes as well as some other external factors, 
which is indicated by its presence in only 2-5% 
of carriers of these two genes, and absence of 
full prevalence in one-egg twins [3, 4, 8, 28].
The significance of HLA class II glycopro-
teins present on the antigen-presenting cells is 
reflected in the characteristic that, after bond-
ing with gliadin peptide hydrolysate formed of 
33 amino acids, they activate intestinal CD4+ 
T-lymphocytes which, by secreting proinflam-
matory cytokines, lead to the infiltrative or in-
filtrative-destructive inflammation of the small 
intestinal mucosa [1, 2, 3, 9]. This process is 
preceded by tissue transglutaminase-mediated 
deamination of the glutamine residue of gliadin 
hydrolysate, which increases the affinity of their 
bonding with HLA DQ2 and DQ8 molecules 
[9, 10]. In addition to T-cell immune response, 
humoral immunity also has an important par-
ticipation in the disease pathogenesis, which is 
confirmed by the presence of autoantibodies to 
reticulin, endomysium, tissue transglutaminase 
and other body structures [1, 2, 3, 9].
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ENTEROPATHY
Damage of the small intestinal mucosa is most expressed in 
the duodenum and the proximal part of the jejunum, while 
progressively decreasing toward the ileum [4]. However, in 
some cases evident mucosal lesions can be present only in 
the duodenal bulbus [4, 33]. According to the modified 
Marsh criteria inflammation of the small intestinal mucosa 
is classified into three basic types: infiltrative (I), infiltra-
tive-hyperplastic (II) and destructive (III) [34]. In the first 
form of mucosal damage there is an increased number of 
intraepithelial lymphocytes with γ/δ receptor properties, as 
well as the lymphoplasmocytic infiltration of the stroma, 
while intestinal villous height and crypt depth remain intact. 
In the second form of damage, beside marked infiltrative 
changes, there is crypt hyperplasia, while in the third one, 
beside a marked infiltration and hyperplasia, there is villous 
flattening and/or loss. According to the degree of mucosal 
damage, destructive enteropathy is additionally classified 
into partial (IIIa), subtotal (IIIb) and total (IIIc) (Figure 1). 
Besides, a fourth form is also possible to occur, which is 
characterized by a total villous atrophy but without crypt 
hyperplasia and typical signs of mucosal inflammation.
CLINICAL FORMS OF THE DISEASE
From the clinical aspect, celiac disease is divided into two 
basic types: symptomatic and asymptomatic (Scheme 1) [9, 
28, 30]. Under the symptomatic form of the disease, which 
is much rarer, classical and atypical clinical presentation 
can be differentiated. The classical form of the disease is 
characterized by chronic diarrhea followed by malabsorp-
tion and secondary malnutrition, while the clinical features 
of the atypical form are predominated by extraintestinal 
(mono or oligosymptomatic) manifestations [1, 2, 3, 9, 30]. 
The classical form of the disease is mainly seen in infants 
and small children and atypical in later ages and in adults 
[1, 2, 3, 12, 28]. In the clinically manifested forms of the 
disease, beside evident enteropathy mostly of more severe 
degree, antbibodies to tissue transglutaminase (AtTG) and 
endomysium (EMA), as well as HLA DQ2 and/or DQ8 are 
registered. As the small intestinal mucosa is characterized 
by a great functional reserve, in a considerable number of 
cases its inflammation can be nonmanifest, so that such a 
form of the disease is called subclinical (silent celiac dis-
ease) [13, 28, 30]. In addition, the asymptomatic character 
is also the feature of the latent (potential) celiac disease, 
which differs from the silent form by a normal appearance 
of the small intestinal mucosa [13, 28, 30].
The classical form of celiac disease is most frequently 
seen at age 9-36 months (Figure 2) [9, 28, 30]. Complaints 
develop gradually and have a progressive course, and in-
volve chronic diarrhea, anorexia, apathy and irritability. 
The insufficient intake and malabsorption of nutritional 
substances consequentially lead to a global malnutrition 
followed by sideropenic anemia, fat tissue loss and bone-
muscle mass reduction. The child’s longitudinal growth 
remains preserved for a relatively long time. In view of the 
concurrent deficit of the organic and mineral part of bones 
classic rickets are rare. Hypoproteinemic edema occurs in 
the most severe cases of the disease. During the first 6-9 
months of life the disease usually presents with a rapid 
and severe clinical course. In rare cases the so called celiac 
crisis can be seen that is characterized by a total gastroin-
testinal insufficiency followed by severe hydroelectrolytic 
and acid-base disorder, drastic loss of body weight and 
exudative enteropathy [1, 35, 36, 37]. Although the classi-
cal form of the disease is most frequently and best inves-
tigated entity, it is known today that it represents only the 
peak of the celiac iceberg and that the highest number of 
Figure 1. Stereomicroscopic and pathohistological appearance of 
small intestinal mucosa with most severe form of damage (Marsh IIIc) Scheme 1. Clinical forms of celiac disease – the celiac iceberg [30] 
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patients, both children and adults, present with the atypi-
cal or asymptomatic form of the disease [13, 28, 30].
In preschool children the onset and the course of the dis-
ease is mostly uncharacteristic (atypical) and more difficult 
to recognize [9, 28, 30]. Most frequently, gastrointestinal 
disorders are absent or slight. There is the presence of recur-
rent abdominal pain and constipation, diarrhea rarely, while 
frequently sideropenic anemia resistant to oral therapy with 
iron, delay in longitudinal growth, marked thinness, osteo-
penia and child’s personality changes. [1, 2, 3, 30].
In later childhood and adolescence symptomatology is 
predominated by mono or oligosymptomatic extraintestinal 
disorders [9, 28, 30]. Beside the manifestations of this type 
that can be seen at previous age, others also develop, such 
as developmental delay, enamel hypoplasia, chronic fatigue, 
arthralgia, myalgia, ataxia, polyneuropathy, epilepsy, alopecia, 
vitiligo, dermatitis herpetiformis and other. Frequently occur-
ring finding, both in these and earlier ages, involve isolated 
hypertransaminasemia, liver steatosis, thrombocytosis, gran-
ulocytosis, osteopenia and lymphocytic gastritis [5, 13, 38].
Possible complications of celiac disease verified with 
delay or inadequately treated that are seen in adult age in-
volve T-cell small intestinal lymphoma, refractory sprue 
and ulcerative jejunoileitis [3]. Recent investigations have 
indicated that the risk of other malignancies is not as high 
as previously considered [2]. A potential complication of 
untreated celiac disease also involves infertility [4].
ASSOCIATION WITH OTHER DISEASES
In addition to a high frequency among close relatives of the 
diseased, particularly those of the first line, celiac disease 
is characterized by a high association (3-10%) with other 
autoimmune diseases, such as diabetes mellitus type I, au-
toimmune thyroiditis, Addison’s disease, juvenile idiopathic 
arthritis, Sjögren’s syndrome, autoimmune liver diseases, 
systemic lupus erythematodes, IgA nephropathy, myasthe-
nia gravis, psoriasis, dilated cardiomyopathy and other [1, 2, 
3, 30, 39]. Approximately identical prevalence of the disease 
is also registered in IgA selective deficit, as well as in Down, 
Turner and Williams syndrome [2, 9, 40].
DIAGNOSTICS
The diagnosis of celiac disease is based on enterobiopsy with 
pathohistological examination of the small intestinal mu-
cosa [1, 2, 3, 41]. According to the latest recommendations 
of the European Society for Pediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) defined in 2010, 
this procedure is not necessary only in patients with symp-
toms and/or signs corresponding to celiac disease, but also 
with present IgA antibodies titer to tissue transglutaminase 
(AtTG) above 100 U/ml, positive anti-endomysial antibod-
ies and “celiac HLA“ (DQ2 and/or DQ8) [42, 43]. In favor 
of the verification of disease presence, i.e. justified intro-
duction of gluten-free diet unpreceded by biopsy, speak the 
patient’s clinical recovery and AtTG disappearance [42, 43]. 
Such attitude in the celiac disease diagnostics is based, not 
only on high sensitivity and specificity of IgA AtTG as a se-
rological marker of the disease (>95%), but also on a highly 
significant correlation of their titer with the degree of small 
intestinal mucosa damage, as well as on the almost unavoid-
able (>98%) presence of HLA DQ2 and/or DQ8 [42, 43]. 
Serological indicators of the disease, such as autoantibodies 
to endomysium and tissue transglutaminase, and antibodies 
to deanimated gliadin peptides have a high sensitivity and 
specificity, but not also an absolute diagnostic validity [1, 2, 
3, 44, 45]. Therefore, they are primarily used in the detec-
tion of asymptomatic and atypical forms of the disease, as 
well as in the assessment of the consistency of elimination 
diet in cases with already verified disease [11, 13, 45, 46]. If 
the diagnosis of celiac disease is exact, according to the latest 
ESPGHAN criteria, the provocation of gluten tolerance with 
a pathohistological analysis of the small intestinal mucosa 
is unnecessary neither in children in whom it was verified 
before completed second year of life [42, 43]. However, in 
patients on gluten-free diet introduced without a preceding 
enterobiopsy, as well as in cases in whom morphological 
mucosal damage was not typical or where samples were in-
adequate for a reliable interpretation, the final confirmation 
or exclusion of celiac disease is based on the biopsy finding 
during gluten tolerance provocation [41, 42, 43]. As this 
procedure can endanger the quality of permanent teeth, it 
is suggested not to be used before completed sixth year of 
life, and due to adverse effects on the child’s growth and 
development neither during puberty [41].
TREATMENT
As celiac disease represents a permanent disorder, the ba-
sis of its treatment forms a life-long gluten-free diet [1, 2, 
Figure 2. A 15-months old boy with celiac disease during diagnostic 
phase (left) and after a year on gluten-free diet (right)  
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3, 47]. In addition, during the initial phase of treatment 
most patients, particularly those with the symptomatic 
form of the disease, require correction of microelements 
and vitamin deficit, above all iron and folates, and in a 
certain number of cases a temporary restriction of lactose 
[2, 48]. In the most severe forms of the disease, beside 
the stabilization of water-salt balance and edema removal, 
semi-elementary and/or additional parenteral nutrition 
is applied, and very rarely a short-term glucocorticoid 
therapy as well [1, 36, 37].
PROGNOSIS
The prognosis of a timely recognized and adequately 
treated celiac disease is excellent [49]. In fact, if all condi-
tions are fulfilled, these persons cannot even be considered 
patients. Late recognition of the disease or non-adherence 
to the gluten-free diet can lead to various complications, 
sometimes even highly severe [11, 49, 50].
CONCLUSION
Celiac disease represents a polygenically determined au-
toimmune disorder induced by gluten in wheat, barley and 
rye. It primarily occurs in Caucasians, and particularly often 
in close relatives of the diseased, as well as in patients with 
other autoimmune diseases; IgA deficit and Down, Turner 
and Williams syndrome. The basis of the disease and the 
key finding in its diagnostics are formed by the non-specific 
inflammation of the small intestinal mucosa that resolves 
by gluten-free diet. Beside enteropathy, either symptomatic 
or asymptomatic, the disease is also characterized by differ-
ent extraintestinal manifestations. If timely recognized and 
adequately treated, the disease prognosis is good.
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КРАТАК САДРЖАЈ
Це ли јач на  бо лест  је  мул ти си стем ско  ауто и мун ско  обо ље-
ње  иза зва но  глу те ном  пше ни це,  ра жи  и  јеч ма.  Од ли ку ју  је 
по ли ген ска пре ди спо зи ци ја, ви со ка пре ва лен ци ја (1%), ве-
о ма  хе те ро ге на  екс пре си ја  и  че ста  удру же ност  са  дру гим 
ауто и мун ским  обо ље њи ма,  се лек тив ним  де фи ци том  IgA и 
Да у но вим (Down), Тар не ро вим (Tur ner) и Ви ли јем со вим (Wil-
li ams)  син дро мом.  Осно ву  бо ле сти  и  кључ ни  на лаз  у  ње ној 
ди јаг но сти ци  чи ни  симп то мат ско  или  асимп то мат ско  за па-
ље ње  слу зо ко же  тан ког  цре ва  ко је  се  по вла чи  на  ди је ти 
без глу те на. Оту да и су шти ну те ра пи је чи ни ели ми на ци о на 
ди је та,  те  овај  по ре ме ћај,  уко ли ко  се  бла го вре ме но  пре по-
зна  и  на  од го ва ра ју ћи  на чин  ле чи,  од ли ку је  и  из ван ред на
  прог но за.
Кључ не  ре чи:  це ли јач на  бо лест;  па то ге не за;  кли нич ки  об-
ли ци;  ди јаг но сти ка;  те ра пи ја
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